Glycopyrrolate; Indacaterol Maleate Patent Expiration
Glycopyrrolate; Indacaterol Maleate is Used for managing airflow obstruction in patients with COPD. It was first introduced by Novartis Pharmaceuticals Corp
Glycopyrrolate; Indacaterol Maleate Patents
Given below is the list of patents protecting Glycopyrrolate; Indacaterol Maleate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Utibron | US8182838 | Dry powder composition comprising co-jet milled particles for pulmonary inhalation | Oct 20, 2028 | Novartis |
| Utibron | US8479730 | Inhaler device | Oct 11, 2028 | Novartis |
| Utibron | US6878721 | Beta2-adrenoceptor agonists | Feb 25, 2025 | Novartis |
| Utibron | US7736670 | Method of making particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Utibron | US8048451 | Pharmaceutical compositions for inhalation |
Jun 27, 2021
(Expired) | Novartis |
| Utibron | US8303991 | Method of making particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Utibron | US8435567 | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation |
Jun 27, 2021
(Expired) | Novartis |
| Utibron | US8580306 | Particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Utibron | US8956661 | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof |
Jun 27, 2021
(Expired) | Novartis |
| Utibron | US9931304 | Method of making particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Utibron | US9962338 | Method of making particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Utibron | US7229607 | Treatment of respiratory disease |
Apr 09, 2021
(Expired) | Novartis |
| Utibron | US8029768 | Treatment of respiratory diseases |
Apr 09, 2021
(Expired) | Novartis |
| Utibron | US7820694 | Beta-2-adrenoreceptor agonists |
Jun 02, 2020
(Expired) | Novartis |
| Utibron | US8067437 | Beta-2-adrenoreceptor agonists |
Jun 02, 2020
(Expired) | Novartis |
| Utibron | US8283362 | Beta-2-adrenoreceptor agonists |
Jun 02, 2020
(Expired) | Novartis |
| Utibron | US8658673 | BETA2-adrenoreceptor agonists |
Jun 02, 2020
(Expired) | Novartis |
| Utibron | US8796307 | Beta2-adrenoreceptor agonists |
Jun 02, 2020
(Expired) | Novartis |
| Utibron | US6582678 | Carrier particles for use in dry powder inhalers |
Apr 24, 2018
(Expired) | Novartis |
| Utibron | US6521260 | Carrier particles for use in dry powder inhalers |
Jan 31, 2016
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Glycopyrrolate; Indacaterol Maleate's patents.
Latest Legal Activities on Glycopyrrolate; Indacaterol Maleate's Patents
Given below is the list recent legal activities going on the following patents of Glycopyrrolate; Indacaterol Maleate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed Critical | 24 Jun, 2024 | US8303991(Litigated) |
| Maintenance Fee Reminder Mailed Critical | 27 May, 2024 | US8283362 |
| Expire Patent Critical | 04 Dec, 2023 | US8048451 |
| Maintenance Fee Reminder Mailed Critical | 19 Jun, 2023 | US8048451 |
| Expire Patent Critical | 27 Mar, 2023 | US8956661 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Mar, 2023 | US8029768 |
| Expire Patent Critical | 28 Nov, 2022 | US7820694 |
| Maintenance Fee Reminder Mailed Critical | 10 Oct, 2022 | US8956661 |
| Expire Patent Critical | 18 Jul, 2022 | US7736670 |
| Maintenance Fee Reminder Mailed Critical | 13 Jun, 2022 | US7820694 |
Glycopyrrolate; Indacaterol Maleate's Family Patents
